Moomoo AI 已提取核心信息
Cassava Sciences, Inc. (Cassava) announced the issuance of up to 25,342,150 shares of its common stock, par value $0.001 per share, upon the exercise of warrants distributed to all holders of common stock on the record date of December 22, 2023. The warrants, issued on January 3, 2024, are transferable and expected to trade on Nasdaq under the ticker SAVAW. Each warrant entitles the holder to purchase one share of common stock at an initial exercise price of $33.00, subject to adjustments, until November 15, 2024. The exercise of the warrants is for cash only. If all warrants are exercised, Cassava would have 67,579,069 shares of common stock issued and outstanding. The company has entered into a warrant agreement with Computershare Trust Company, N.A., as the Warrant Agent. The proceeds from the exercise of the warrants are intended for general corporate purposes, including supporting ongoing clinical trials. The offering involves substantial risks, and the company advises investors to read the 'Risk Factors' section of the prospectus supplement dated January 3, 2024, before buying shares.
Cassava Sciences, Inc. (Cassava) announced the issuance of up to 25,342,150 shares of its common stock, par value $0.001 per share, upon the exercise of warrants distributed to all holders of common stock on the record date of December 22, 2023. The warrants, issued on January 3, 2024, are transferable and expected to trade on Nasdaq under the ticker SAVAW. Each warrant entitles the holder to purchase one share of common stock at an initial exercise price of $33.00, subject to adjustments, until November 15, 2024. The exercise of the warrants is for cash only. If all warrants are exercised, Cassava would have 67,579,069 shares of common stock issued and outstanding. The company has entered into a warrant agreement with Computershare Trust Company, N.A., as the Warrant Agent. The proceeds from the exercise of the warrants are intended for general corporate purposes, including supporting ongoing clinical trials. The offering involves substantial risks, and the company advises investors to read the 'Risk Factors' section of the prospectus supplement dated January 3, 2024, before buying shares.
木薯科学公司（Cassava）宣布，在2023年12月22日创纪录的日期行使分配给所有普通股持有人的认股权证后，将发行最多25,342,150股普通股，面值每股0.001美元。这些认股权证于2024年1月3日发行，可转让，预计将在纳斯达克上市，股票代码为SAVAW。每份认股权证使持有人有权在2024年11月15日之前以33.00美元的初始行使价购买一股普通股，但须进行调整。认股权证的行使仅限现金。如果行使所有认股权证，Cassava将发行和流通67,579,069股普通股。该公司已与作为认股权证代理人的北卡罗来纳州Computershare信托公司签订了认股权证协议。行使认股权证的收益用于一般公司用途，包括支持正在进行的临床试验。此次发行涉及重大风险，该公司建议投资者在购买股票之前阅读2024年1月3日招股说明书补充文件中的 “风险因素” 部分。
木薯科学公司（Cassava）宣布，在2023年12月22日创纪录的日期行使分配给所有普通股持有人的认股权证后，将发行最多25,342,150股普通股，面值每股0.001美元。这些认股权证于2024年1月3日发行，可转让，预计将在纳斯达克上市，股票代码为SAVAW。每份认股权证使持有人有权在2024年11月15日之前以33.00美元的初始行使价购买一股普通股，但须进行调整。认股权证的行使仅限现金。如果行使所有认股权证，Cassava将发行和流通67,579,069股普通股。该公司已与作为认股权证代理人的北卡罗来纳州Computershare信托公司签订了认股权证协议。行使认股权证的收益用于一般公司用途，包括支持正在进行的临床试验。此次发行涉及重大风险，该公司建议投资者在购买股票之前阅读2024年1月3日招股说明书补充文件中的 “风险因素” 部分。
有用
没用